

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Duvelisib. [Updated 2019 Oct 23]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Duvelisib

Revised: October 23, 2019.

CASRN: 1201438-56-3

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of duvelisib during breastfeeding. Because duvelisib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during duvelisib therapy and for at least 1 month after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Duvelisib

CAS Registry Number

1201438-56-3

Drug Class

Lactation

Breast Feeding

Antineoplastic Agents

Enzyme Inhibitors

Kinase Inhibitors

Phosphatidylinositol 3-kinases